SCHEMBL406092

SCHEMBL406092

CB(O)N1CCN(c2nc3cc(F)c(Cl)cc3nc2Cl)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 7/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
GLP1R P43220 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.34
FABP4 P15090 1/20 0.34
FABP5 Q01469 1/20 0.34
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
GPR6 P46095 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405647 0.89 HRH4 (0.41) HRH4HTR3BHTR3ACYP11B1CYP11B2
SCHEMBL406619 0.88 HRH4 (0.40) HRH4HTR3BHTR3ACYP11B1CYP11B2
SCHEMBL13334867 0.85 HRH4 (0.39) HRH4HTR3BHTR3ACYP11B1CYP11B2
SCHEMBL404215 0.82 HRH4 (0.61) HRH4HTR3BHTR3ASMN1; SMN2
SCHEMBL405677 0.80 HRH4 (0.40) HRH4HTR3BHTR3ACYP11B1CYP11B2
SCHEMBL405578 0.80 HRH4 (0.66) HRH4HTR3BHTR3AMAPTPOLB
SCHEMBL406090 0.77 GPR6 (0.35) HRH4CYP11B1CYP11B2GPR6
SCHEMBL406215 0.76 MAPT (0.48) HRH4CYP11B1CYP11B2MAPTSMN1; SMN2
SCHEMBL406219 0.76 HTR3E (0.51) HRH4HTR3BHTR3ACYP11B1CYP11B2
SCHEMBL406322 0.75 HRH4 (0.67) HRH4HTR3BHTR3ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HTR3B 113/4885HTR3A 153/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HTR3B 113/4885HTR3A 153/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HTR3B 113/4885HTR3A 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.